Citation Impact
Citing Papers
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
2008 Standout
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
2018 Standout
Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study
2012
Oral antiplatelet therapy for acute ischaemic stroke
2014
Inhibition of growth hormone release after the combined administration of CHRH and GHRP‐6 in patients with Cushing's syndrome
1994
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
2009
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists
2013
Growth hormone-releasing peptide and its analogues
1995
Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects
1995
Tirofiban for the treatment of ischaemic stroke
2005
Effects of the Antifungal Agents on Oxidative Drug Metabolism
2000
Hexarelin, a potent GHRP analogue: Interactions with GHRH and clonidine in young and aged dogs
1995
Optimising antiemetic therapy: what are the problems and how can they be overcome?
2005
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists
2008
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
2003
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Prevention and Treatment of Respiratory Syncytial Virus and Parainfluenza Viruses in Immunocompromised Patients
1997
Ghrelin?a hormone with multiple functions
2004
Oral Anticoagulant Therapy
2012 Standout
A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients*
2006
Cushing's syndrome
2015 Standout
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
2001 Standout
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
2009
ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects
2001
Albumin–drug interaction and its clinical implication
2013 Standout
GH Releasing Peptides - Structure and Kinetics
1993
Cardiovascular safety of sildenafil citrate (Viagra®): An updated perspective
2006
Eprosartan
1998
Growth hormone releasing peptides: A comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells
1997
5-Hydroxytryptamine3receptor antagonists and cardiac side effects
2014
The effect of an opiate antagonist on the hormonal changes induced by hexarelin
1995
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Meloxicam, 15 mg/day, spares platelet function in healthy volunteers*1
1999
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Growth hormone-releasing activity of hexarelin in humans
1994
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial
2004 Standout
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
2000 Standout
Stroke
2008 Standout
Growth hormone-releasing hormone and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone-releasing peptide-6
1996
Gout
2016 Standout
COX-2???Specific Inhibitors: Definition of a New Therapeutic Concept
2001
Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
2013 Standout
Antiplatelet therapy for acute ischaemic stroke
2003
Growth hormone-releasing peptide (GHRP)
1998
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
Cyclooxygenase 1 and 2 in rheumatic disease: Implications fornonsteroidal anti-inflammatory drug therapy
1996
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
1998
Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats
1998
The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
2006
Systematic Overview of Warfarin and Its Drug and Food Interactions
2005 Standout
A review on emerging contaminants in wastewaters and the environment: Current knowledge, understudied areas and recommendations for future monitoring
2014 Standout
Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP‐6
1993
Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes
1996
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
2005 Standout
Analysis of the reactions used for the preparation of drug candidate molecules
2006 Standout
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Short Sleep Duration Is Associated with Reduced Leptin, Elevated Ghrelin, and Increased Body Mass Index
2004 Standout
Ghrelin: Structure and Function
2005 Standout
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients
2012
On the Actions of the Growth Hormone-Releasing Hexapeptide, GHRP*
1991
Preventable stroke and stroke prevention
2005
Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine
1998
Demonstration and characterization of the specific binding of growth hormone-releasing peptide to rat anterior pituitary and hypothalamic membranes
1991
Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs
2011
Global epidemiology of gout: prevalence, incidence and risk factors
2015 Standout
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Guidelines for the Early Management of Adults With Ischemic Stroke
2007 Standout
In vitro characterization of four novel classes of growth hormone-releasing peptide.
1995
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*
1998 Standout
Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in the Management of Ischemic Stroke
2003
2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
2011 Standout
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
2013 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016
2019 Standout
The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin
1999
MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism1
1998
Growth hormone secretion after the administration of GHRP‐6 or GHRH combined with GHRP‐6 does not decline in late adulthood
1995
Sexually Transmitted Diseases Treatment Guidelines, 2010
2011 Standout
Effect of Growth Hormone (GH)-Releasing Peptide (GHRP) on the Release of GH from Cultured Anterior Pituitary Cells in Cattle.
1994
Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease
2003
Prolongation of QTc Interval after Postoperative Nausea and Vomiting Treatment by Droperidol or Ondansetron
2005
Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue.
1993
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
2000 Standout
Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone.
1992
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents
2021 StandoutNobel
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.
1996
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
2009
Intranasal Administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (Growth Hormone Releasing Peptide) Increased Plasma Growth Hormone and Insulin-like Growth Factor-I Levels in Normal Men.
1991
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
Engineered Bacterial Mimics of Human Drug Metabolizing Enzyme CYP2C9
2011 StandoutNobel
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
Cyclooxygenase in biology and disease
1998 Standout
Gout
2021 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men.
1992
Effect of Angiotensin II Antagonist Eprosartan on Hyperglycemia-Induced Activation of Intrarenal Renin-Angiotensin System in Healthy Humans
2000
Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension
2010
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
1999 StandoutNature
The Development of a Manufacturing Route for the GPIIb/IIIa Receptor Antagonist SB-214857-A. Part 1: Synthesis of the Key Intermediate 2,3,4,5-Tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic Acid Methyl Ester, SB-235349
2003
Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep.
1994
Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
2001
Neuroendocrine Control of Growth Hormone Secretion
1999
Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
1993
Works of Bernard E. Ilson being referenced
Evaluation of vardenafil and sildenafil on cardiac repolarization
2004
Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food
1998
Pharmacokinetics and Protein Binding of Eprosartan in Healthy Volunteers and in Patients with Varying Degrees of Renal Impairment
1998
Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers
1997
Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial
2000
A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men*
1998
EFFECT OF A NEW SYNTHETIC HEXAPEPTIDE TO SELECTIVELY STIMULATE GROWTH HORMONE RELEASE IN HEALTHY HUMAN SUBJECTS
1989
Comparative Effects of Nabumetone, Sulindac, and Indomethacin on Urinary Prostaglandin Excretion and Platelet Function in Volunteers
1994
Eprosartan Does Not Affect the Pharmacodynamics of Warfarin
1998
Fenoldopam Reverses Cyclosporine-Induced Renal Vasoconstriction in Kidney Transplant Recipients
1992
Eprosartan, an Angiotensin II Receptor Antagonist, Does Not Affect the Pharmacodynamics of Glyburide in Patients with Type II Diabetes Mellitus
1997
Steady‐State Pharmacokinetics of Carvedilol and Its Enantiomers in Patients with Congestive Heart Failure
2000
The Effects of Eprosartan, an Angiotensin II AT1 Receptor Antagonist, on Uric Acid Excretion in Patients with Mild to Moderate Essential Hypertension
1998
Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*
1997
Pharmacokinetics and Protein Binding of Eprosartan in Hemodialysis‐Dependent Patients with End‐Stage Renal Disease
1999
Effect of age and gender on the pharmacokinetics of eprosartan
1998
The Pharmacokinetics, Antigenicity, and Fusion-Inhibition Activity of RSHZ19, a Humanized Monoclonal Antibody to Respiratory Syncytial Virus, in Healthy Volunteers
1996
A Dose Proportionality Study of Eprosartan in Healthy Male Volunteers
1998
Effect of Hepatic Disease on the Pharmacokinetics and Plasma Protein Binding of Eprosartan
1998
CARDIOVASCULAR MONITORING IN NORMAL HEALTHY ADULTS
1995
Cardiovascular Monitoring in Normal Healthy Adults: A Literature Review and Recommendations for the Reporting of Disturbances of Cardiac Rhythm.
1995
Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults
1997
Effect of Ranitidine on the Pharmacokinetics of Orally Administered Eprosartan, an Angiotensin II Antagonist, in Healthy Male Volunteers
1998